Sarcoendoplasmic Reticulum Calcium Transport ATPase 2a: A Potential Gene Therapy Target in Heart Failure

Cardiology in Review

Volumn 21, Issue 3, 2013, Pages 151-154

  Papolos, Alexander ^a   Frishman, William H ^b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

cardiomyopathy; CUPID trial; gene therapy; heart failure; SERCA2a

Indexed keywords

SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; UNCLASSIFIED DRUG;

EXCITATION CONTRACTION COUPLING; GENE TARGETING; GENE THERAPY; HEART FAILURE; HEART MUSCLE CELL; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW;

ANIMALS; CLINICAL TRIALS AS TOPIC; GENETIC THERAPY; HEART FAILURE; HUMANS; RATS; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SHEEP;

EID: 84876412524     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3182749cdb     Document Type: Review

References (23)

1. Meyer M, Schillinger W, Pieske B, et al. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation. 1995;92:778-784.
2. Hasenfuss G, Reinecke H, Studer R, et al. Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium. Circ Res. 1994;75:434-442.
3. Shenoy SK, Rockman HA. Cardiovascular biology: heart fails without pump partner. Nature. 2011;477:546-547.
4. Schmidt U, Hajjar RJ, Kim CS, et al. Human heart failure: cAMP stimulation of SR Ca(2+)-ATPase activity and phosphorylation level of phospholamban. Am J Physiol. 1999;277(2 Pt 2):H474-H480. (Pubitemid 29415959)
5. Periasamy M, Bhupathy P, Babu GJ. Regulation of sarcoplasmic reticulum Ca2+ ATPase pump expression and its relevance to cardiac muscle physiology and pathology. Cardiovasc Res. 2008;77:265-273. (Pubitemid 351197644)
6. Lipskaia L, Ly H, Kawase Y, et al. Treatment of heart failure by calcium cycling gene therapy. Future Cardiol. 2007;3:413-423. (Pubitemid 47050211)
7. Kho C, Lee A, Jeong D, et al. SUMO1-dependent modulation of SERCA2a in heart failure. Nature. 2011;477:601-605.
8. Vejlstrup NG, Bouloumie A, Boesgaard S, et al. Inducible nitric oxide synthase (iNOS) in the human heart: expression and localization in congestive heart failure. J Mol Cell Cardiol. 1998;30:1215-1223. (Pubitemid 28327789)
9. Lokuta AJ, Maertz NA, Meethal SV, et al. Increased nitration of sarcoplasmic reticulum Ca2+-ATPase in human heart failure. Circulation. 2005;111:988-995. (Pubitemid 40354516)
10. Prasad AM, Inesi G. Silencing calcineurin A subunit reduces SERCA2 expression in cardiac myocytes. Am J Physiol Heart Circ Physiol. 2011;300:H173-H180.
11. Prasad AM, Inesi G. Regulation and rate limiting mechanisms of Ca2+ ATPase (SERCA2) expression in cardiac myocytes. Mol Cell Biochem. 2012;361:85-96.
12. del Monte F, Harding SE, Schmidt U, et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation. 1999;100:2308-2311.
13. del Monte F, Williams E, Lebeche D, et al. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation. 2001;104:1424-1429. (Pubitemid 32880157)
14. Sakata S, Lebeche D, Sakata N, et al. Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins. J Mol Cell Cardiol. 2007;42:852-861. (Pubitemid 46527593)
15. Niwano K, Arai M, Koitabashi N, et al. Lentiviral vector-mediated SERCA2 gene transfer protects against heart failure and left ventricular remodeling after myocardial infarction in rats. Mol Ther. 2008;16:1026-1032. (Pubitemid 351737066)
16. Beeri R, Chaput M, Guerrero JL, et al. Gene delivery of sarcoplasmic reticulum calcium ATPase inhibits ventricular remodeling in ischemic mitral regurgitation. Circ Heart Fail. 2010;3:627-634.
17. Mariani JA, Smolic A, Preovolos A, et al. Augmentation of left ventricular mechanics by recirculation-mediated AAV2/1-SERCA2a gene delivery in experimental heart failure. Eur J Heart Fail. 2011;13:247-253.
18. Kumarswamy R, Lyon AR, Volkmann I, et al: SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt/Fox03A-dependent pathway. Eur Heart J 2012;33:1067-75.
19. Tilemann L, Ishikawa K, Weber T, et al. Gene therapy for heart failure. Circ Res. 2012;110:777-793.
20. Jaski BE, Jessup ML, Mancini DM, et al.; Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID) Trial Investigators. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail. 2009;15:171-181.
21. Jessup M, Greenberg B, Mancini D, et al.; Calcium Upregulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID) Investigators. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation. 2011;124:304-313.
22. Celladon Corporation. A study of genetically targeted enzyme replacement therapy for advanced heart failure (CUPID 2b). ClinicalTrials.gov Identifier: NCT01643330. Accessed February 19, 2013
23. Imperial College London. Investigation of the safety and feasibility of SERCA gene transfer in the human failing heart using an adeno-associated viral vector. ClinicalTrials.gov Identifier: NCT00534703